Prognosis of Diffusely Infiltrative Esophageal Squamous Cell Carcinoma After Radical Esophagectomy

被引:0
作者
Tamura, Masahiro [1 ]
Mine, Shinji [1 ]
Watanabe, Takehiro [1 ]
Yoshimoto, Yutaro [1 ]
Asakura, Takanobu [1 ]
Ozaki, Asako [1 ]
Yube, Yukinori [1 ]
Kaji, Sanae [1 ]
Fujiwara, Daisuke [1 ]
Hashiguchi, Tadasuke [1 ]
Nasu, Motomi [1 ]
Orita, Hajime [1 ]
Hashimoto, Takashi [1 ]
Fukunaga, Tetsu [1 ]
机构
[1] Juntendo Univ Hosp, Dept Esophageal & Gastroenterol Surg, Tokyo, Japan
关键词
esophagectomy; squamous cell carcinoma; Type 4 esophageal cancer; LYMPH-NODE DISSECTION; BORRMANN TYPE-IV; NEOADJUVANT TREATMENT; CANCER; CHEMOTHERAPY; RADIOTHERAPY; DOCETAXEL; PATTERNS;
D O I
10.1002/wjs.12618
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundDiffusely infiltrative esophageal squamous cell carcinoma is rare, and the benefit of surgical resection for this disease remains unclear. In this study, we investigated the prognosis of diffusely infiltrative squamous cell carcinoma compared with other macroscopic types of locally advanced esophageal cancer. Additionally, we aimed to identify prognostic factors for this disease.MethodsEligible patients were limited to macroscopic types 1 to 4 with histological classification restricted to squamous cell carcinoma. Patients who underwent R2 resection were excluded, resulting in 850 patients being selected for analysis. The eligible patients were divided into two groups: Type 4 and non-Type 4. Survival rates were calculated using the Kaplan-Meier method with statistical significance assessed via the log-rank test. Prognostic factors were evaluated using Cox proportional hazards regression.ResultsNo significant differences in patient background characteristics or preoperative factors were observed between Type 4 and non-Type 4 groups. However, postoperative pathological findings revealed that Type 4 had a significantly greater number of lymph node metastases. Univariate and multivariate analyses identified Type 4 as an independent poor prognostic factor. Furthermore, the Type 4 group had more pleural recurrences and shorter survival times after recurrence than the non-Type 4 group.ConclusionType 4 esophageal cancer itself was an independent poor prognostic factor, possibly because of the greater number of pathological nodal metastases and poor responsiveness after recurrence. Although approximately 20% of patients who underwent esophagectomy could achieve long-term survival, further development of multidisciplinary treatment for Type 4 esophageal cancer is crucial.
引用
收藏
页码:1583 / 1590
页数:8
相关论文
共 30 条
[1]   Borrmann type IV: An independent prognostic factor for survival in gastric cancer [J].
An, Ji Yeong ;
Kang, Tae Ho ;
Choi, Min Gew ;
Noh, Jae Hyung ;
Sohn, Tae Sung ;
Kim, Sung .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (08) :1364-1369
[2]  
Christodoulidis Grigorios, 2025, World J Exp Med, V15, P96318, DOI [10.5493/wjem.v15.i1.96318, 10.5493/wjem.v15.i1.96318]
[3]   Novel imaging techniques in staging oesophageal cancer [J].
Foley, Kieran ;
Findlay, John ;
Goh, Vicky .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2018, 36-37 :17-25
[4]   Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer [J].
Hashiguchi, Tadasuke ;
Nasu, Motomi ;
Hashimoto, Takashi ;
Kuniyasu, Tetsuji ;
Inoue, Hirohumi ;
Sakai, Noritaka ;
Ouchi, Kazutomo ;
Amano, Taicayuki ;
Isayama, Fuyumi ;
Tomita, Natsumi ;
Iwanuma, Yoshimi ;
Tsurumaru, Masahiko ;
Kajiyama, Yoshiaki .
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) :719-724
[5]  
Japan Esophageal Disease Research Society, 2002, COMPREHENSIVE REGIST
[6]  
Kajiyama Y., 2006, ESOPHAGUS, V3, P189, DOI [10.1007/s10388-006-0092-6, DOI 10.1007/S10388-006-0092-6]
[7]  
Kajiyama Y., 2007, J JPN SURG ASS, V68, P795, DOI [10.3919/jjsa.68.795, DOI 10.3919/JJSA.68.795]
[8]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458
[9]   Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial [J].
Kato, Ken ;
Machida, Ryunosuke ;
Ito, Yoshinori ;
Daiko, Hiroyuki ;
Ozawa, Soji ;
Ogata, Takashi ;
Hara, Hiroki ;
Kojima, Takashi ;
Abe, Tetsuya ;
Bamba, Takeo ;
Watanabe, Masaya ;
Kawakubo, Hirofumi ;
Shibuya, Yuichi ;
Tsubosa, Yasuhiro ;
Takegawa, Naoki ;
Kajiwara, Takeshi ;
Baba, Hideo ;
Ueno, Masaki ;
Takeuchi, Hiroya ;
Nakamura, Kenichi ;
Kitagawa, Yuko .
LANCET, 2024, 404 (10447) :55-66
[10]   Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial [J].
Kato, Ken ;
Cho, Byoung Chul ;
Takahashi, Masanobu ;
Okada, Morihito ;
Lin, Chen-Yuan ;
Chin, Keisho ;
Kadowaki, Shigenori ;
Ahn, Myung-Ju ;
Hamamoto, Yasuo ;
Doki, Yuichiro ;
Yen, Chueh-Chuan ;
Kubota, Yutaro ;
Kim, Sung-Bae ;
Hsu, Chih-Hung ;
Holtved, Eva ;
Xynos, Ioannis ;
Kodani, Mamoru ;
Kitagawa, Yuko .
LANCET ONCOLOGY, 2019, 20 (11) :1506-1517